Akira Fujii1, Koichi Nagashima2, Saurabh Kumar2, Shinichi Tanigawa2, Samuel H Baldinger2, Gregory F Michaud2, Roy M John2, Bruce A Koplan2, Michifumi Tokuda2, Keiichi Inada2, Usha B Tedrow2, William G Stevenson1. 1. From the Arrhythmia Unit, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (A.F., S.K., S.T., S.H.B., G.F.M., R.M.J., B.A.K., M.T., K.I., U.B.T., W.G.S.); and Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan (K.N.). william.g.stevenson@vanderbilt.edu akfujii@m.ehime-u.ac.jp. 2. From the Arrhythmia Unit, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (A.F., S.K., S.T., S.H.B., G.F.M., R.M.J., B.A.K., M.T., K.I., U.B.T., W.G.S.); and Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan (K.N.).
Abstract
BACKGROUND: Noninducibility of sustained monomorphic ventricular tachycardia (SMVT) postablation does not insure absence of later recurrence in patients with ischemic cardiomyopathy. This study aims to determine the relation between inducible nonsustained VT postablation and VT recurrences. METHODS AND RESULTS: One hundred sixty-five consecutive patients (156 male; age 68±9 years) underwent ablation for SMVT because of ischemic cardiomyopathy; 44 patients who did not have induction testing or in whom only ventricular fibrillation was induced after ablation were excluded. In 38 patients (23%), SMVT was inducible (group C). Of the 83 patients without inducible SMVT after ablation, nonsustained VT defined as ≥5 beats lasting for <30 s, was induced in 34 patients (group B, 21%), whereas the remaining 49 patients had no VT induced by the induction test (group A, 30%). Over a median follow-up of 18.7 months, freedom from recurrent VT at 24 months was 60% in group A, 45% in group B (P=0.017 versus group A), and 38% in group C (P=0.005 versus group A). In patients without inducible SMVT, inducible nonsustained VT and left ventricular ejection fraction was independently associated with VT recurrence (hazard ratio, 3.66 and 1.07; 95% CI, 1.3-11.1 and 1.01-1.14). CONCLUSIONS: Inducible nonsustained VT postablation suggests the continued presence of functional arrhythmia substrate. Further trials are needed to assess whether additional ablation would improve outcome in this group.
BACKGROUND: Noninducibility of sustained monomorphic ventricular tachycardia (SMVT) postablation does not insure absence of later recurrence in patients with ischemic cardiomyopathy. This study aims to determine the relation between inducible nonsustained VT postablation and VT recurrences. METHODS AND RESULTS: One hundred sixty-five consecutive patients (156 male; age 68±9 years) underwent ablation for SMVT because of ischemic cardiomyopathy; 44 patients who did not have induction testing or in whom only ventricular fibrillation was induced after ablation were excluded. In 38 patients (23%), SMVT was inducible (group C). Of the 83 patients without inducible SMVT after ablation, nonsustained VT defined as ≥5 beats lasting for <30 s, was induced in 34 patients (group B, 21%), whereas the remaining 49 patients had no VT induced by the induction test (group A, 30%). Over a median follow-up of 18.7 months, freedom from recurrent VT at 24 months was 60% in group A, 45% in group B (P=0.017 versus group A), and 38% in group C (P=0.005 versus group A). In patients without inducible SMVT, inducible nonsustained VT and left ventricular ejection fraction was independently associated with VT recurrence (hazard ratio, 3.66 and 1.07; 95% CI, 1.3-11.1 and 1.01-1.14). CONCLUSIONS: Inducible nonsustained VT postablation suggests the continued presence of functional arrhythmia substrate. Further trials are needed to assess whether additional ablation would improve outcome in this group.
Authors: Javier Jiménez-Candil; Olga Duran; Armando Oterino; Jendri Pérez; Juan Carlos Castro; Jesús Hernández; José Moríñigo; Manuel Sánchez García; Pedro L Sánchez Journal: BMC Cardiovasc Disord Date: 2021-05-31 Impact factor: 2.298